{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:07:12Z","timestamp":1791648432541,"version":"4.3.4"},"reference-count":42,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The ORAL Surveillance trial found a dose\u2010dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with rheumatoid arthritis (RA) aged 50 years or older with at least one\u2009additional cardiovascular risk factor received tofacitinib 5 or 10 mg twice daily (BID) or TNFi. Post hoc, cumulative probabilities and incidence rates (patients with first events\/100 patient\u2010years) by 6\u2010month intervals were estimated for adjudicated VTE, deep vein thrombosis, and PE. Cox regression models identified risk factors. Clinical Disease Activity Index leading up to the event was explored in patients with VTE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cumulative probabilities for VTE and PE were higher with tofacitinib 10\u2009mg BID, but not 5 mg BID, versus TNFi. Incidence rates were consistent across 6\u2010month intervals within treatments. Across treatments, risk factors for VTE included prior VTE, body mass index greater than or equal to 35 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , older age, and history of chronic lung disease. At the time of the event, most patients with VTE had active disease as defined by Clinical Disease Activity Index.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Incidences of VTE and PE were higher with tofacitinib (10 &gt; 5 mg BID) versus TNFi and were generally consistent over time. Across treatments, VTE risk factors were aligned with previous studies in the general RA population. These data highlight the importance of assessing VTE risk factors, including age, body mass index, and VTE history, when considering initiation of tofacitinib or TNFi in patients with active RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.42846","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T01:00:31Z","timestamp":1710378031000},"page":"1218-1229","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk\u2010Enriched Rheumatoid Arthritis Patients"],"prefix":"10.1002","volume":"76","author":[{"given":"Christina","family":"Charles\u2010Schoeman","sequence":"first","affiliation":[{"name":"University of California Los Angeles  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Metroplex Clinical Research Center and University of Texas Southwestern Medical Center  Dallas Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n M\u00e9dica de Investigaci\u00f3n  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Greenwald","sequence":"additional","affiliation":[{"name":"Desert Medical Advances  Palm Desert California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Ytterberg","sequence":"additional","affiliation":[{"name":"Mayo Clinic  Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary G.","family":"Koch","sequence":"additional","affiliation":[{"name":"The University of North Carolina at Chapel Hill  Chapel Hill North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Health System  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0897-2272","authenticated-orcid":false,"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center and Veterans Affairs Nebraska Western Iowa Health Care System  Omaha Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"All\u2010shine","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Connell","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Woolcott","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Menon","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Lee","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-6844","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[{"name":"University of Debrecen  Debrecen Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203380"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22039"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0435-y"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/2012.jama.11741"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2013.20.2.118"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.10.012"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105122"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161212799504731"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32658-1"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-015-1311-6"},{"key":"e_1_2_8_13_1","first-page":"233","article-title":"Elevated risk of venous thromboembolic events in patients with inflammatory myopathies","volume":"12","author":"Nowak M","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.08.003"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.11.055"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S46310"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.006472"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.709204"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.9.935"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.7.729"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024507"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200726"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.4537"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002571"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X231201047"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223715"},{"key":"e_1_2_8_28_1","unstructured":"US Food and Drug Administration.Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate.2019. Accessed May 30 2022.https:\/\/www.fda.gov\/media\/120485\/download"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-4825(92)90023-G"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"issue":"5","key":"e_1_2_8_32_1","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha D","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216761"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223916"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001618"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40841"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00402-2015"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218419"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05121-4"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001515"},{"key":"e_1_2_8_43_1","unstructured":"Clinicaltrials.gov.A study of baricitinib (LY3009104) in participants with rheumatoid arthritis (RA\u2010BRIDGE).2021. Accessed March 28 2024.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03915964"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:07:22Z","timestamp":1759932442000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/art.42846"],"URL":"https:\/\/doi.org\/10.1002\/art.42846","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"2022-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}